Anti-Osteoporosis and Fracture Healing Market |
Anti-Osteoporosis and Fracture Healing Market by Drug Type (Bi-phosphates, Calcitonin, Estrogen or Hormone Replacement Therapy, Others), by Route of administration (Oral, Injectable, Others) and by DISTRIBUTION CHANNEL (Hospital Pharmacy, Drug Stores, Retail Pharmacy, E-commerce) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
The global Anti-Osteoporosis
and Fracture Healing Market is estimated to be valued at US$
13.80 billion in 2023 and is expected to exhibit a CAGR of 8.51 % over the
forecast period as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Several numerous fractures are complex by
impaired curative. This is widespread in specific life-threatening groups such
as geriatric, osteoporotic, and menopause women and in people suffering from
malnutrition. Hence, there is an unfilled necessity for medications that can
heal the bone. Parathyroid hormone anti-osteoporosis and fracture healing is
the primary bone anabolic drug approved for the therapy of osteoporosis and
enthrallingly several animal surveys prove the capability of anti –osteoporosis
and fracture healing to persuade fracture healing. Anti-Osteoporosis and
fracture healing might further be a potential new therapy chance in people with
impaired recovery.
Competitive
Landscape:
Key players involved in the growth of global Anti-Osteoporosis and Fracture Healing
Market are F.Hoffmann La Roche Ltd., Eli Lilly and Company, Merck and
Company Inc., Actavis plc, Novartis International AG., Teva Pharmaceutical
Industries Ltd., Amgen Inc., Pfizer, Inc., and GlaxoSmithKline plc.
Market Key Drivers:
Rising prevalence of osteoporosis in women is
expected to drive the growth of global Anti-Osteoporosis and Fracture Healing
Market. For instance, as per IOF around 200 million women across the globe
suffer from osteoporosis.
Rise of bone diseases due to the changing
lifestyle is projected to propel the growth of global Anti-Osteoporosis and
Fracture Healing Market. For instance, as per NIH over 1.5 million people
across the globe suffer from bone disease.
Covid-19 Impact
Analysis:
The Covid-19 outbreak had adversely affected
the growth of the global Anti-Osteoporosis
and Fracture Healing Market due to the surge in pandemic. The cases has led
to the strict imposition of lockdown and restricted the visits to hospitals. The
delay in visits to hospitals and shutdown of some clinics to curb the spread of
virus is known to impede the market growth.
Key Takeaways:
The global Anti-Osteoporosis and Fracture
Healing Market is expected to exhibit a CAGR of 8.51 % during the forecast
period owing to the rising approvals, launches, mergers and acquisitions. For
instance In September 2018, the U.S. FDA Administration approved the promotion
of Risedronate Sodium Delayed release capsules in America.
0 Comments